Gefitinib-induced hemorrhagic cystitis and inflammatory contracted bladder in a patient with advanced lung adenocarcinoma harboring compound epidermal growth factor receptor G719S and S768I missense mutations: a case report

BACKGROUND: Numerous clinical studies have established the efficacy and safety of gefitinib for treating patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. Gefitinib-induced urinary system-related adverse reactions are rare but may lead to discontinuation of gefitinib. CASE DE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xueli, Cheng, Jiande, Zhao, Lifen, Cheng, Mengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372651/
https://www.ncbi.nlm.nih.gov/pubmed/35965829
http://dx.doi.org/10.21037/atm-22-3233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372651/
https://www.ncbi.nlm.nih.gov/pubmed/35965829
http://dx.doi.org/10.21037/atm-22-3233

Ejemplares similares